DOSEGUY

Vilon

guinea pig

Also seen as: KE, Lys-Glu, Vilon peptide

The Dose Guy’s verdict
Sep 1, 2026
3 sources

The smallest of the Khavinson bioregulators, a two-amino-acid peptide studied for immune function and aging, and one of the few with both promising and troubling animal data. In one mouse model it extended lifespan and prevented spontaneous tumors. In another it accelerated mammary cancer at p below 0.05. I am not running a peptide with a published tumor-promotion signal and zero human safety data. If the bioregulator concept interests you, thymalin has human studies and no tumor flag.

Would I take it?No. Not with a cancer signal on file.

What it is

Vilon is the Lys-Glu dipeptide, the shortest peptide in the bioregulator family. It acts as a thymomimetic, mimicking the thymus gland’s role in immune-cell maturation. In cell work it upregulates SIRT1, the longevity-associated sirtuin, in mesenchymal stem cells and modulates inflammatory cytokines in THP-1 monocytes. Two Russian clinical abstracts exist for type 1 diabetes, but neither reports quantified outcomes, so the human evidence is a placeholder, not a foundation.

What makes vilon unusual among its siblings is the range of its animal data. Thymalin has human studies. Testagen has only cell and bird experiments. Vesugen has one small human report. Vilon has rodent data that points in two directions at once, which is arguably worse, because it means the peptide is doing something you cannot predict.

What the research shows

A split data set that should make you pause:

Subcutaneous vilon started at 6 months of age prolonged lifespan in female CBA mice and prevented spontaneous neoplasm development.animal · CBA mouse lifespan · 2000
In HER-2 neu transgenic mice, vilon increased mammary cancer incidence, shortened mean tumor latency, and increased cumulative tumor count, each at p below 0.05.animal · HER-2 transgenic mice · 2002
In young human mesenchymal stem cells, vilon increased SIRT1 gene expression 6-fold and SIRT1 protein synthesis 8.2-fold.in vitro · human MSC aging · 2023
No human trial abstract reports adverse-event rates for vilon, and no human pharmacokinetic study exists.as of Aug 2026

Realistic protocols

A peptide that extended lifespan in one mouse strain and accelerated cancer in another is not something I will dress up with a dosing table. The community runs vilon the same way it runs the other bioregulators: short courses of subcutaneous injections, typically 10 to 20 days, then months off. If you run it, keep courses short, and do not pretend that “short peptide, low dose” means “harmless.” The HER-2 result happened at standard bioregulator dosing.

Side effects

The animal data carries the safety story here:

monitorIn HER-2 transgenic mice, vilon increased mammary cancer incidence and shortened tumor latency. If you have a family history of hormone-sensitive cancer, this is a stop sign, not a speed bump.
anecdotalInjection-site irritation, consistent with the bioregulator class.
unknownNo human adverse-event rates exist. The animal data says vilon is not inert, which is exactly why human safety data matters and does not exist.

Where to buy

No live listings from tracked vendors right now.